Prostate cancer: genetics, epigenetics and the need for immunological biomarkers

Epidemiological data highlight prostate cancer as a significant global health issue, with high incidence and substantial impact on patients' quality of life. The prevalence of this disease is associated with various factors, including age, heredity, and race. Recent research in prostate cancer...

Full description

Bibliographic Details
Published in:International journal of molecular sciences Vol. 24, № 16. P. 12797 (1-27)
Other Authors: Rafikova, Guzel, Gilyazova, Irina, Enikeeva, Kadriia, Pavlov, Valentin N., Kzhyshkowska, Julia G.
Format: Article
Language:English
Subjects:
Online Access:http://vital.lib.tsu.ru/vital/access/manager/Repository/koha:001133511
Перейти в каталог НБ ТГУ
LEADER 03633nab a2200409 c 4500
001 koha001133511
005 20240418193502.0
007 cr |
008 240416|2023 sz s a eng d
024 7 |a 10.3390/ijms241612797  |2 doi 
035 |a koha001133511 
040 |a RU-ToGU  |b rus  |c RU-ToGU 
245 1 0 |a Prostate cancer: genetics, epigenetics and the need for immunological biomarkers  |c G. Rafikova, I. Gilyazova, K. Enikeeva [et al.] 
336 |a Текст 
337 |a электронный 
504 |a Библиогр.: 216 назв. 
520 3 |a Epidemiological data highlight prostate cancer as a significant global health issue, with high incidence and substantial impact on patients' quality of life. The prevalence of this disease is associated with various factors, including age, heredity, and race. Recent research in prostate cancer genetics has identified several genetic variants that may be associated with an increased risk of developing the disease. However, despite the significance of these findings, genetic markers for prostate cancer are not currently utilized in clinical practice as reliable indicators of the disease. In addition to genetics, epigenetic alterations also play a crucial role in prostate cancer development. Aberrant DNA methylation, changes in chromatin structure, and microRNA (miRNA) expression are major epigenetic events that influence oncogenesis. Existing markers for prostate cancer, such as prostate-specific antigen (PSA), have limitations in terms of sensitivity and specificity. The cost of testing, follow-up procedures, and treatment for false-positive results and overdiagnosis contributes to the overall healthcare expenditure. Improving the effectiveness of prostate cancer diagnosis and prognosis requires either narrowing the risk group by identifying new genetic factors or enhancing the sensitivity and specificity of existing markers. Immunological biomarkers (both circulating and intratumoral), including markers of immune response and immune dysfunction, represent a potentially useful area of research for enhancing the diagnosis and prognosis of prostate cancer. Our review emphasizes the need for developing novel immunological biomarkers to improve the diagnosis, prognosis, and management of prostate cancer. We highlight the most recent achievements in the identification of biomarkers provided by circulating monocytes and tumor-associated macrophages (TAMs). We highlight that monocyte-derived and TAM-derived biomarkers can enable to establish the missing links between genetic predisposition, hormonal metabolism and immune responses in prostate cancer. 
653 |a рак 
653 |a генетика 
653 |a эпигенетика 
653 |a микроокружение опухоли 
653 |a моноциты 
653 |a рак предстательной железы 
653 |a биомаркеры рака 
655 4 |a статьи в журналах  |9 958055 
700 1 |a Rafikova, Guzel  |9 958054 
700 1 |a Gilyazova, Irina  |9 958056 
700 1 |a Enikeeva, Kadriia  |9 958057 
700 1 |a Pavlov, Valentin N.  |9 884969 
700 1 |a Kzhyshkowska, Julia G.  |9 102999 
773 0 |t International journal of molecular sciences  |d 2023  |g Vol. 24, № 16. P. 12797 (1-27)  |x 1661-6596 
852 4 |a RU-ToGU 
856 4 |u http://vital.lib.tsu.ru/vital/access/manager/Repository/koha:001133511 
856 |y Перейти в каталог НБ ТГУ  |u https://koha.lib.tsu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=1133511 
908 |a статья 
999 |c 1133511  |d 1133511 
039 |b 100